ARX-720 is under clinical development by Bristol-Myers Squibb and currently in Phase II for Congestive Heart Failure (Heart Failure). According to GlobalData, Phase II drugs for Congestive Heart Failure (Heart Failure) have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ARX-720’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ARX-720 is under development for the treatment of heart failure. The drug candidate targets and enhances the activity relaxin peptide receptor. It is based on ReCODE platform technology. This technology modifies the native proteins with amino acid building blocks beyond the common 20 to engineer enhanced versions for investigation for therapeutic use.
Bristol-Myers Squibb overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.
For a complete picture of ARX-720’s drug-specific PTSR and LoA scores, buy the report here.